DEFA14A ·Filed Apr 17, 2026

EXEL

EXELIXIS, INC.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001628280-26-025746
Proxy solicitation materials
Actionable Insight • Neutral

Investors should note the voting implications for Proposal No. 3, particularly that abstentions will negatively impact passage. However, no material change to corporate strategy, governance, or financials is indicated.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
EXEL ▲ +27.95% at T+60d
NEUTRAL call ✓ call won +27.95% · α vs SPY +21.87% · entry $43.59 → $55.77
Entry anchored
Apr 17, 03:59 PM ET
via exchange tick
T+1d
+5.25%
call +5.25% · α +5.91%
$45.88
settled 6mo ago
T+5d
+2.13%
call +2.13% · α +1.22%
$44.52
settled 5mo ago
T+20d
+14.32%
call +14.32% · α +10.11%
$49.83
settled 5mo ago
T+60d
+27.95%
call +27.95% · α +21.87%
$55.77
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Exelixis, Inc. filed a supplement to its definitive proxy statement to clarify the voting standard for Proposal No. 3, which relates to the approval of the Amended 2017 Plan. The clarification specifies that a majority of shares present or represented by proxy is required for approval, with abstentions counting as votes against and broker non-votes having no effect.

Key Facts

  • The filing is a supplement to the DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders.
  • The sole purpose is to correct the voting standard description for Proposal No. 3 (Amended 2017 Plan).
  • The required vote is a majority of shares present or represented by proxy; abstentions count as votes against, broker non-votes have no effect.
  • No other changes are made to the original proxy statement.

Financial Impact

No direct financial impact; this is a procedural clarification.

Risk Factors

  • If shareholder support is close, the clarified voting standard could affect the outcome of Proposal No. 3 due to the treatment of abstentions.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001628280-26-025746
Document: 0001628280-26-025746-index-headers.html0001628280-26-025746
Document: 0001628280-26-025746-index.html0001628280-26-025746
Document: 0001628280-26-025746.txt0001628280-26-025746
12 reports for EXEL
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +21.97%Feb 28, 2026
Filters
Rows
Reports for EXEL — sortable, filterable
TypeNow
Sep 11, 2026
21d ago
8-K
BEARISH ★ 6/10
$56.12 $58.36▼ −3.99%▼ −4.21%$58.38 (−4.03%)
Aug 10, 2026
7w ago
Press Release
BEARISH ★ 7/10
$51.33 $53.10▼ −3.44%▼ −3.85%$58.38 (−13.73%)
Jun 3, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$52.39 $53.50▲ +2.12%▲ +4.68%$58.38 (+11.44%)
May 29, 2026
17w ago
8-K
NEUTRAL ★ 3/10
$50.20 $52.70▲ +4.98%▲ +7.73%$58.38 (+16.30%)
May 28, 2026
18w ago
Insider Cluster
NEUTRAL ★ 3/10
$50.32 $51.60▲ +2.55%▲ +2.84%$58.38 (+16.02%)
May 28, 2026
18w ago
Insider Cluster
NEUTRAL ★ 3/10
$50.32 $51.60▲ +2.55%▲ +2.84%$58.38 (+16.02%)
May 28, 2026
18w ago
Insider Cluster
NEUTRAL ★ 3/10
$50.32 $52.69▲ +4.71%▲ +7.23%$58.38 (+16.02%)
May 22, 2026
18w ago
Insider Cluster
NEUTRAL ★ 3/10
$49.94 $48.49▼ −2.90%▼ −4.12%$58.38 (+16.90%)
May 19, 2026
19w ago
Insider Cluster
NEUTRAL ★ 3/10
$49.89 $51.46▲ +3.15%▲ +1.34%$58.38 (+17.02%)
May 7, 2026
21w ago
Insider Cluster
NEUTRAL ★ 2/10
$46.10 $51.29▲ +11.26%▲ +9.76%$58.38 (+26.64%)
Showing 10 of 12

US Market Status

Market Open — Closes in 6h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access